ADC Therapeutics
Manufacturing · Switzerland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Biopôle 3b, Epalinges, Vaud, 1066, Switz...Phone Number
+41 216530200Website
www.adctherapeutics.comRevenue
$79.6 MillionStock Symbol
ADCTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ADC Therapeutics
ADC Therapeutics SA is a global biotechnology company focused on the discovery, development, commercialization, and advancement of antibody drug conjugate therapies for the treatment of cancer. The company specializes in creating targeted oncology medicines designed to selectively attack cancer cells while minimizing the impact on healthy tissue. By combining advanced antibody engineering with potent therapeutic payloads, ADC Therapeutics develops innovative treatments intended to improve clinical outcomes for patients facing difficult-to-treat cancers.Explore more
ADC Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ADC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ADC Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at ADC Therapeutics
Check out if ADC Therapeutics is spiking on competitors!
Product Launch: Get notified when ADC Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ADC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
ADC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ADC Therapeutics has new funding data
Click to see if ADC Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined ADC Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
ADC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ADC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ADC Therapeutics.
ADC Therapeutics financials insights
Gather financial insights about ADC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$40M
2015
Unspecified
$80M
2016
Share Placement
$105M
Series D
$105M
2019
Series E
$303M
2020
Stock Offering
$267.6M
2022
Debt
$175M
Private Equity
$6.3M
2025
Stock/Share Issuance
$100M
ADC Therapeutics Tech Stack
A closer look at the technologies used by ADC Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Layoffs
Layoffs, Financial Planning, Pharmaceuticals, Clinical Operations, Finance, Financial Strategy
ADC Therapeutics News & Media
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsNicole Riley - Head of Investor Relations & Corporate...ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier...ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30...ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ADC Therapeutics
Sign Up For FreeTo access detailed company insights
ADC Therapeutics SA is a global biotechnology company focused on the discovery, development, commercialization, and advancement of antibody drug conjugate therapies for the treatment of cancer. The company specializes in creating targeted oncology medicines designed to selectively attack cancer cells while minimizing the impact on healthy tissue. B... Read More
